PMID- 25260877
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 15
IP  - 17
DP  - 2014 Dec
TI  - Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
PG  - 2487-500
LID - 10.1517/14656566.2014.965678 [doi]
AB  - INTRODUCTION: The dramatic rise in the prevalence of obesity and type 2 diabetes 
      mellitus (T2DM) is associated with increased mortality, morbidity as well as 
      public health care expenses worldwide. The need for effective and long-lasting 
      pharmaceutical treatment is obvious. The record of anti-obesity drugs has been 
      poor so far and the only efficient treatment today is bariatric surgery. Research 
      has indicated that appetite inhibiting hormones from the gut may have a 
      therapeutic potential in obesity. The gut incretin hormone, glucagon-like 
      peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways 
      mediating satiety. Clinical trials have shown that two GLP-1 receptor agonists 
      exenatide and liraglutide have a weight-lowering potential in non-diabetic obese 
      individuals. Furthermore, they may also hold a potential in preventing diabetes 
      as compared to other weight loss agents. AREAS COVERED: The purpose of this 
      review is to cover the background for the GLP-1-based therapies and their 
      potential in obesity and pre-diabetes. Up-to-date literature on incretin-based 
      therapies will be summarized with a special mention of their weight-lowering 
      properties. The literature updated to August 2014 from PubMed was identified 
      using the combinations: GLP-1, GLP-1 receptor agonists, incretins, obesity and 
      pre-diabetes. EXPERT OPINION: The incretin impairment, which seems to exist in 
      both obesity and diabetes, may link these two pathologies and underlines the 
      potential of GLP-1-based therapies in the prevention and treatment of these 
      diseases.
FAU - Iepsen, Eva W
AU  - Iepsen EW
AD  - University of Copenhagen, Department of Biomedical Sciences, Faculty of Health 
      and Medical Sciences , Blegdamsvej 3B, Copenhagen 2200 , Denmark.
FAU - Torekov, Signe S
AU  - Torekov SS
FAU - Holst, Jens J
AU  - Holst JJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140926
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Glucagon)
RN  - 0 (Venoms)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
EIN - Expert Opin Pharmacother. 2015 Jan;16(1):147. PMID: 25490726
MH  - Anti-Obesity Agents/*therapeutic use
MH  - Appetite/physiology
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/prevention & control
MH  - Exenatide
MH  - Glucagon-Like Peptide 1/analogs & derivatives/*metabolism/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incretins/metabolism
MH  - Liraglutide
MH  - Obesity/*drug therapy/metabolism
MH  - Peptides/therapeutic use
MH  - Prediabetic State/drug therapy/metabolism
MH  - Receptors, Glucagon/*agonists
MH  - Venoms/therapeutic use
OTO - NOTNLM
OT  - glucagon-like peptide 1
OT  - glucagon-like peptide 1 receptor agonists
OT  - incretins
OT  - obesity
OT  - pre-diabetes
OT  - type 2 diabetes mellitus
EDAT- 2014/09/28 06:00
MHDA- 2015/03/03 06:00
CRDT- 2014/09/28 06:00
PHST- 2014/09/28 06:00 [entrez]
PHST- 2014/09/28 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
AID - 10.1517/14656566.2014.965678 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2014 Dec;15(17):2487-500. doi: 
      10.1517/14656566.2014.965678. Epub 2014 Sep 26.